Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and BL-8040 in Metastatic Pancreatic Cancer
NCT02907099Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2016
- Primary completion
- Oct 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of motixafortide in pancreatic adenocarcinoma (PDAC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Response Rate at 3 years. Started Dec 2016; status: completed.
02
Drugs
motixafortide
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02907099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02907099.